You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 10,022,440


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,022,440
Title:Materials and methods for modulating immune responses
Abstract: The present invention provides materials and methods for modulating an immune response. In one embodiment, the present invention provides an initial artificial lymph-node homing environment, and a simultaneous, or subsequent, artificial spleen environment leading to the resolution of the activated immune responses. In one specific embodiment, the present invention can be used to prevent and/or treat pathogenic infection, cancer, allergenic reactions, and/or unwanted immune or auto-immune responses.
Inventor(s): Wasserfall; Clive Henry (Gainesville, FL), Atkinson; Mark A. (Gainesville, FL), Keselowsky; Benjamin George (Gainesville, FL), Yoon; Young Mee (Gainesville, FL)
Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (Gainesville, FL)
Application Number:14/117,122
Patent Claims:1. A method for inducing a protective immune response against a target autoantigen, wherein the method comprises administering, to a subject in need of such an immune response, a pro-inflammatory adjuvant and an anti-inflammatory adjuvant, wherein said method further comprises administering the target autoantigen; wherein the pro-inflammatory adjuvant comprises one or more of the following: cytosine-guanosine (CpG) oligonucleotide (CpG-ODN) sequences, a CpG rich oligonucleotide, incomplete Freund's adjuvant, complete Freund's adjuvant, and Freund's adjuvant with muramyldipeptide (MDP); wherein the anti-inflammatory adjuvant comprises one or more of the following: hemoglobin:haptoglobin, hemin, heme:hemopexin, ethyl pyruvate (EP), anti Thymocyte Globulin, and anti-CD3; and wherein the target autoantigen is an autoantigen of Type 1 diabetes selected from insulin, proinsulin, the B chain of insulin, glutamic acid decarboxylase (GAD), and insulinoma associated-2-protein (IA-2).

2. The method, according to claim 1, wherein the anti-inflammatory adjuvant comprises one or more of the following: hemoglobin:haptoglobin, hemin, and ethyl pyruvate (EP).

3. The method, according to claim 1, wherein the anti-inflammatory adjuvant is administered after the pro-inflammatory adjuvant.

4. The method, according to claim 1, wherein the pro-inflammatory adjuvant and the anti-inflammatory adjuvant are administered simultaneously.

5. The method, according to claim 1, further comprising administering an immuno-modulating molecule that induces the migration of an immune cell.

6. The method, according to claim 5, wherein the immuno-modulating molecule is selected from GM-CSF, G-CSF, or both.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.